McKesson Launches Multi-Year Strategic Growth Initiative; Reaffirms Fiscal 2018 Outlook and Provides Preliminary Fiscal 2019 Outlook

  • McKesson announces a multi-year growth initiative, focused on
    creating innovative new solutions that improve patient care delivery
    and drive shareholder value.
  • Fiscal 2018 Outlook: Adjusted Earnings of $12.50 to $12.80 per
    diluted share.
  • Preliminary Fiscal 2019 Outlook: Adjusted Earnings of $13.00 to
    $13.80 per diluted share.
  • The company has scheduled a conference call for 8:30 AM ET
    tomorrow, Thursday, April 26, to discuss these updates.

SAN FRANCISCO–(BUSINESS WIRE)–McKesson Corporation (NYSE:MCK) today announced a multi-year strategic
growth initiative, focused on creating innovative new solutions that
improve patient care delivery and drive incremental profit growth. The
initiative comprises multiple growth pillars, and includes a
comprehensive review of the company’s operations and cost structure,
designed to increase efficiency, accelerate execution and improve
long-term performance.

McKesson’s growth priorities include expanded supply chain and
commercialization services for pharmaceutical and medical supply
manufacturers; enhanced solutions for the rapidly-growing specialty
pharmaceutical market, and; new offerings that will strengthen and
expand the role of retail pharmacy in patient care delivery. McKesson
expects investments in these areas will accelerate the company’s growth
trajectory over the long term.

Investment to support these growth initiatives will be partially funded
by savings from the optimization of McKesson’s operating model and cost
structure. This work will take place in multiple phases and will
encompass key functional areas such as information technology, finance
and human resources.

McKesson has constantly innovated in response to changing customer and
patient needs,” said John H. Hammergren, chairman and chief executive
officer. “This initiative continues that tradition, building on our
prior successes while focusing on new areas where we can have the
greatest impact on patient care while driving profit growth. By
embracing better ways of working and becoming more efficient and agile,
we can support innovation while creating more value for customers,
patients and shareholders.”

As a preliminary phase of implementing the strategic growth initiative,
McKesson will incur restructuring and other charges in Fiscal 2019,
which will impact the company’s results on the basis of U.S. generally
accepted accounting principles (“GAAP”). This restructuring plan
consists of after-tax GAAP charges that are estimated to be
approximately $150 million to $210 million.

McKesson is also announcing today that it has signed a definitive
agreement to acquire Medical Specialties Distributors (MSD), a leading
national distributor of infusion and medical-surgical supplies as well
as biomedical services to alternate site and home health providers.

This transaction supports two of the company’s strategic growth
pillars–manufacturer services and specialty–and complements the
company’s existing low-cost site of care infusion platform. MSD’s
established offering to providers in the home infusion market, as well
as technology and services to support customers and patients using these
products, will allow McKesson to provide incremental services to other
customer segments.

The transaction is valued at $800 million, and is expected to close in
the first half of Fiscal 2019, subject to customary closing conditions,
including necessary regulatory clearances. McKesson expects the
transaction will be modestly accretive to Adjusted Earnings per diluted
share in Fiscal 2019.

Fiscal 2018 Outlook

The company has reaffirmed its Adjusted Earnings outlook of $12.50 to
$12.80 per diluted share for the fiscal year ended March 31, 2018. The
Adjusted Earnings outlook is anticipated to benefit primarily from a
lower adjusted tax rate and better operational performance than
expected, offset by a pre-tax contribution of $100 million, or $0.31 per
diluted share, related to the creation of a non-profit foundation
dedicated to addressing issues stemming from the nation’s opioid
epidemic as previously announced on March 29, 2018.

The company expects the newly-created foundation to focus on opioid
education for patients, caregivers, and providers, addressing key policy
issues, and increasing access to life-saving treatments, such as opioid
overdose reversal medications. Please visit www.mckesson.com
to learn more about the company’s initiatives to combat the opioid
epidemic.

Further, in the fourth quarter, the company preliminarily estimates
recording GAAP after-tax net charges of approximately $0.6 billion to
$1.9 billion. These estimated charges, which will be reflected in the
company’s GAAP results, are driven primarily by goodwill and long-lived
asset impairments related to McKesson’s European and Rexall businesses
and the early repayment of long-term debt, net of estimated benefits
related to adjustments to the Federal tax reform provisional amounts
initially recorded last quarter.

Preliminary Fiscal 2019 Outlook

McKesson is in the budget development process for Fiscal 2019 and is
announcing a preliminary target for Adjusted Earnings of $13.00 to
$13.80 per diluted share.

McKesson will provide detailed financial guidance for Fiscal 2019 when
fourth quarter and Fiscal 2018 earnings results are reported on
Thursday, May 24, 2018.

Conference Call Details

The company has scheduled a thirty-minute conference call for tomorrow,
Thursday, April 26, at 8:30 AM ET. The dial-in number for individuals
wishing to participate on the call is 323-794-2551. Craig Mercer, senior
vice president, Investor Relations, is the leader of the call, and the
password to join the call is ‘McKesson’. A telephonic replay of this
conference call will be available for five calendar days. The dial-in
number for individuals wishing to listen to the replay is 719-457-0820
and the pass code is 7951872. An archive of the conference call will
also be available on the company’s Investor Relations website at http://investor.mckesson.com.

Dividend Declaration

The company’s Board of Directors today declared a regular dividend of
$0.34 cents per share of common stock. The dividend will be payable on
July 2, 2018, to stockholders of record on June 1, 2018.

Adjusted Earnings

McKesson separately reports financial results on the basis of Adjusted
Earnings. Adjusted Earnings is a non-GAAP financial measure defined as
GAAP income from continuing operations, excluding amortization of
acquisition-related intangible assets, acquisition-related expenses and
adjustments, LIFO inventory-related adjustments, gains from antitrust
legal settlements, restructuring charges, and other adjustments.

Risk Factors

Except for historical information contained in this press release,
matters discussed may constitute “forward-looking statements” within the
meaning of Section 27A of the Securities Act of 1933 and Section 21E of
the Securities Exchange Act of 1934, as amended, that involve risks and
uncertainties that could cause actual results to differ materially from
those projected, anticipated or implied. These statements may be
identified by their use of forward-looking terminology such as
“believes”, “expects”, “anticipates”, “may”, “will”, “should”, “seeks”,
“approximately”, “intends”, “plans”, “estimates” or the negative of
these words or other comparable terminology. The discussion of financial
trends, strategy, plans or intentions may also include forward-looking
statements. It is not possible to predict or identify all such risks and
uncertainties; however, the most significant of these risks and
uncertainties are described in the company’s Form 10-K, Form 10-Q and
Form 8-K reports filed with the Securities and Exchange Commission and
include, but are not limited to: changes in the U.S. healthcare industry
and regulatory environment; managing foreign expansion, including the
related operating, economic, political and regulatory risks; changes in
the Canadian healthcare industry and regulatory environment; exposure to
European economic conditions, including recent austerity measures taken
by certain European governments; changes in the European regulatory
environment with respect to privacy and data protection regulations;
fluctuations in foreign currency exchange rates; the company’s ability
to successfully identify, consummate, finance and integrate
acquisitions; the company’s ability to manage and complete divestitures;
material adverse resolution of pending legal proceedings; competition
and industry consolidation; substantial defaults in payment or a
material reduction in purchases by, or the loss of, a large customer or
group purchasing organization; the loss of government contracts as a
result of compliance or funding challenges; public health issues in the
U.S. or abroad; cyberattack, natural disaster, or malfunction of
sophisticated internal computer systems to perform as designed; the
adequacy of insurance to cover property loss or liability claims; the
company’s failure to attract and retain customers for its software
products and solutions due to integration and implementation challenges,
or due to an inability to keep pace with technological advances; the
company’s proprietary products and services may not be adequately
protected, and its products and solutions may be found to infringe on
the rights of others; system errors or failure of our technology
products or services to conform to specifications; disaster or other
event causing interruption of customer access to data residing in our
service centers; the delay or extension of our sales or implementation
cycles for external software products; changes in circumstances that
could impair our goodwill or intangible assets; new or revised tax
legislation or challenges to our tax positions; general economic
conditions, including changes in the financial markets that may affect
the availability and cost of credit to the company, its customers or
suppliers; changes in accounting principles generally accepted in the
United States of America; withdrawal from participation in multiemployer
pension plans or if such plans are reported to have underfunded
liabilities; inability to realize the expected benefits from the
company’s restructuring and business process initiatives; difficulties
with outsourcing and similar third party relationships; risks associated
with the company’s retail expansion; and the company’s inability to keep
existing retail store locations or open new retail locations in
desirable places. The reader should not place undue reliance on
forward-looking statements, which speak only as of the date they are
first made. Except to the extent required by law, the company undertakes
no obligation to publicly release the result of any revisions to these
forward-looking statements to reflect events or circumstances after the
date hereof, or to reflect the occurrence of unanticipated events.

Shareholders are encouraged to review the company’s filings with the
Securities and Exchange Commission.

About McKesson Corporation

McKesson Corporation, currently ranked 5th on the FORTUNE
500, is a global leader in healthcare supply chain management solutions,
retail pharmacy, community oncology and specialty care, and healthcare
information technology. McKesson partners with pharmaceutical
manufacturers, providers, pharmacies, governments and other
organizations in healthcare to help provide the right medicines, medical
products and healthcare services to the right patients at the right
time, safely and cost-effectively. United by our ICARE shared
principles, our employees work every day to innovate and deliver
opportunities that make our customers and partners more successful — all
for the better health of patients. McKesson has been named the “Most
Admired Company
” in the healthcare wholesaler category by FORTUNE, a
Best
Place to Work
” by the Human Rights Campaign Foundation, and a top military-friendly
company
 by Military Friendly. For more information, visit www.mckesson.com.

Contacts

McKesson Corporation
Craig Mercer, 415-983-8391 (Investors and
Financial Media)
Craig.Mercer@McKesson.com
Kristin
Hunter Chasen, 415-983-8974 (General and Business Media)
Kristin.Chasen@McKesson.com

Aurinia to Present at the Bloom Burton & Co. Healthcare Investor Conference on May 3, 2018

VICTORIA, British Columbia–(BUSINESS WIRE)–Aurinia Pharmaceuticals Inc., (NASDAQ:AUPH)(TSX:AUP) today announced
that Celia Economides, Vice President, Corporate and Public Affairs,
will present at the Bloom Burton & Co. Healthcare Investor Conference on
Thursday, May 3rd at 1:30pm EDT. A webcast will be available
and can be accessed via the investor section of the Aurinia website, www.auriniapharma.com.
A replay will also be archived on the site following the event.

About Aurinia
Aurinia is a clinical stage
biopharmaceutical company focused on developing and commercializing
therapies to treat targeted patient populations that are suffering from
serious diseases with a high unmet medical need. The company is
currently developing voclosporin, an investigational drug, for the
treatment of LN, FSGS, and DES. The company is headquartered in
Victoria, BC and focuses its development efforts globally. For further
information, see our website at www.auriniapharma.com.

About the Conference
The Bloom Burton & Co.
Healthcare Investor Conference brings together U.S., Canadian and
international investors who are interested in the latest developments in
the Canadian healthcare sector. Attendees will have an opportunity to
obtain corporate updates from the premier Canadian publicly traded and
private companies through presentations and private meetings.

About Bloom Burton & Co.
Bloom Burton & Co.
(Bloom Burton Securities Inc.) is a firm dedicated to accelerating
returns in the healthcare sector for both investors and companies. Bloom
Burton has an experienced team of medical, scientific, pharmaceutical,
legal and capital markets professionals who perform a deep level of
diligence, which combined with our creative and entrepreneurial
approach, assists our clients in achieving the right monetization
events. Bloom Burton and its affiliates provide capital raising, M&A
advisory, equity research, business strategy and scientific consulting,
advisory on direct investing and company creation and incubation
services. Bloom Burton Securities Inc. is a member of the Investment
Industry Regulatory Organization of Canada (IIROC) and is also a member
of the Canadian Investor Protection Fund (CIPF).

We seek safe harbor.

Contacts

Aurinia Pharmaceuticals Inc.
Investor Contact:
Celia
Economides
VP, Corporate & Public Affairs
IR@auriniapharma.com
or
Media:
Christopher
Hippolyte, 212-364-0458
Christopher.hippolyte@inventivhealth.com

Deciphera Pharmaceuticals, Inc. to Report Clinical Data with DCC-2618 at the Upcoming 2018 American Society for Clinical Oncology (ASCO) Annual Meeting

WALTHAM, Mass.–(BUSINESS WIRE)–$DCPH #ASCO18–Deciphera Pharmaceuticals, Inc. (NASDAQ:DCPH), a clinical-stage
biopharmaceutical company focused on addressing key mechanisms of tumor
drug resistance, today announced that an abstract highlighting DCC-2618,
the Company’s KIT and PDGFRα inhibitor, has been selected for poster
presentation and discussion at the 2018 American Society for Clinical
Oncology (ASCO) Annual Meeting, taking place June 1-5, 2018 in Chicago,
IL.

Details of the presentation on DCC-2618 are as follows:

Poster Title: Mutation profile of drug resistant
gastrointestinal stromal tumor (GIST) patients (pts) enrolled in the
phase 1 study of DCC-2618.

Author: Suzanne George, Dana-Farber Cancer Institute
Session:
Sarcoma, Poster and Discussion Session
Abstract #: 11511
Poster
Board #:
256
Date & Time: Saturday June 2, 2018 3:00
PM – 4:15 PM CT
Location: Hall A, S404, McCormick Place,
Chicago, IL

About DCC-2618

DCC-2618 is a KIT and PDGFRα kinase switch control inhibitor in clinical
development for the treatment of KIT and/or PDGFRα-driven cancers,
including gastrointestinal stromal tumors, or GIST, systemic
mastocytosis, or SM, and glioblastoma multiforme. DCC-2618 was
specifically designed to improve the treatment of GIST patients by
inhibiting a broad spectrum of mutations in KIT and PDGFRα. DCC-2618 is
a KIT and PDGFRα inhibitor that blocks initiating and secondary KIT
mutations in exons 9, 11, 13, 14, 17, and 18, involved in GIST as well
as the primary D816V exon 17 mutation involved in SM. DCC-2618 also
inhibits primary PDGFRα mutations in exons 12, 14,and 18, including the
exon 18 D842V mutation, involved in a subset of GIST.

About Deciphera Pharmaceuticals

Deciphera Pharmaceuticals is a clinical-stage biopharmaceutical company
focused on improving the lives of cancer patients by tackling key
mechanisms of drug resistance that limit the rate and/or durability of
response to existing cancer therapies. Our small molecule drug
candidates are directed against an important family of enzymes called
kinases, known to be directly involved in the growth and spread of many
cancers. We use our deep understanding of kinase biology together with a
proprietary chemistry library to purposefully design compounds that
maintain kinases in a “switched off” or inactivated conformation. These
investigational therapies comprise tumor-targeted agents designed to
address therapeutic resistance causing mutations and immuno-targeted
agents designed to control the activation of immunokinases that suppress
critical immune system regulators, such as macrophages. We have used our
platform to develop a diverse pipeline of tumor-targeted and
immuno-targeted drug candidates designed to improve outcomes for
patients with cancer by improving the quality, rate and/or durability of
their responses to treatment.

Availability of Other Information About Deciphera Pharmaceuticals

Investors and others should note that Deciphera Pharmaceuticals
communicates with its investors and the public using its company website
(www.deciphera.com),
including but not limited to investor presentations and scientific
presentations, Securities and Exchange Commission filings, press
releases, public conference calls and webcasts. The information that
Deciphera Pharmaceuticals posts on these channels and websites could be
deemed to be material information. As a result, Deciphera
Pharmaceuticals encourages investors, the media and others interested in
Deciphera Pharmaceuticals to review the information that it posts on
these channels, including Deciphera Pharmaceuticals’ investor relations
website, on a regular basis. This list of channels may be updated from
time to time on Deciphera Pharmaceuticals’ investor relations website
and may include other social media channels than the ones described
above. The contents of Deciphera Pharmaceuticals’ website or these
channels, or any other website that may be accessed from its website or
these channels, shall not be deemed incorporated by reference in any
filing under the Securities Act of 1933, as amended.

Cautionary Note Regarding Forward-Looking Statements

This press release contains forward-looking statements within the
meaning of the Private Securities Litigation Reform Act of 1995, as
amended, including, without limitation, statements regarding the
potential for DCC-2618 to treat GIST SM, glioblastoma multiforme and
other diseases; statements regarding the potential benefits to patients
of DCC-2618; statements regarding plans and timelines for the clinical
development of DCC-2618; and Deciphera Pharmaceuticals’ strategy,
business plans and focus. The words “may,” “will,” “could,” “would,”
“should,” “expect,” “plan,” “anticipate,” “intend,” “believe,”
“estimate,” “predict,” “project,” “potential,” “continue,” “target” and
similar expressions are intended to identify forward-looking statements,
although not all forward-looking statements contain these identifying
words. Any forward-looking statements in this press release are based on
management’s current expectations and beliefs and are subject to a
number of risks, uncertainties and important factors that may cause
actual events or results to differ materially from those expressed or
implied by any forward-looking statements contained in this press
release, including, without limitation, statements regarding the
potential for DCC-2618 to treat GIST SM, glioblastoma multiforme and
other diseases; statements regarding the potential benefits to patients
of DCC-2618; statements regarding plans and timelines for the clinical
development of DCC-2618; and Deciphera Pharmaceuticals’ strategy,
business plans and focus. These and other risks and uncertainties are
described in greater detail in the section entitled “Risk Factors” in
Deciphera Pharmaceuticals’ most recent annual report on Form 10-K, and
other filings that Deciphera Pharmaceuticals may make with the SEC in
the future. Any forward-looking statements contained in this press
release represent Deciphera Pharmaceuticals’ views only as of the date
hereof and should not be relied upon as representing its views as of any
subsequent date. Deciphera Pharmaceuticals explicitly disclaims any
obligation to update any forward-looking statements.

Contacts

Media:
The Yates Network
Gina Nugent, 617-460-3579
gina@theyatesnetwork.com
or
Investor
Relations:
Argot Partners
Laura Perry or Sam Martin,
212-600-1902
Laura@argotpartners.com or Sam@argotpartners.com
or
Company:
Deciphera
Pharmaceuticals, Inc.
Christopher J. Morl, 781-209-6418
Chief
Business Officer
cmorl@deciphera.com

Lattice Biologics Ltd. Announces Update to Management Cease Trade Order

BELGRADE, Mont.–(BUSINESS WIRE)–Lattice Biologics Ltd. (TSX-V:
LBL
) (OTCQB:
LBLTF
) (“Lattice Biologics” or the “Company”) is
providing this default status report in accordance with National Policy
12-203 – Management Cease Trade Orders. The Company’s audited
annual financial statements, related management’s discussion and
analysis and accompanying CEO and CFO certifications for the financial
year ended September 30, 2017 (collectively, the “Required Filings”)
would not be completed by the prescribed period for the filing of such
documents under Parts 4 and 5 of National Instrument 51-102 respecting
Continuous Disclosure Obligations and pursuant to National Instrument
52-109 respecting Certification of Disclosure in Issuer’s Annual and
Interim Filings, being September 30th, 2017.

As a result of this delay in the filing of the Required Filings, the
British Columbia Securities Commission granted a management cease trade
order (the “MCTO”) on January 30th, 2018 against the Company’s Chief
Executive Officer and Chief Financial Officer, rather than a general
cease trade order against the Company. The MCTO restricts all trading in
securities of the Company, whether direct or indirect, by the Chief
Executive Officer and Chief Financial Officer of the Company until such
time as the Required Filings have been filed by the Company. The MCTO
does not generally affect the ability of shareholders who are not
insiders of the Company to trade their securities.

The Company expects it will file the Required Filings by April 30th,
2018. The audit process is underway and the Company is working closely
with its auditors and expects to complete the remaining steps in order
to file the Required Filings.

The Company intends to satisfy the provisions of the alternative
information guidelines set out in sections 4.3 and 4.4 of National
Policy 12-203 Management Cease Trade Orders by issuing bi-weekly default
status reports in the form of further news releases, which will be filed
on SEDAR, until the Required Filings have been filed.

The Company confirms as of the date of this news release that there is
no insolvency proceeding against it and there is no other material
information concerning the affairs of the Company that has not been
generally disclosed. The Company would file, to the extent applicable,
its next default status report on or about April 30th, 2018.

Subscribe
to Lattice News Updates

Follow us on Twitter: @LatticeBio

Contacts

Lattice Biologics Ltd.
Cheryl Farmer, CFO
480-563-0800 Office
News@LatticeBiologics.com
www.LatticeBiologics.com

Syntimmune Appoints Andrew Cheng, M.D., Ph.D., to Board of Directors, Bolstering Clinical Development Expertise

BOSTON–(BUSINESS WIRE)–Syntimmune,
Inc
., a clinical-stage biotechnology company developing antibody
therapeutics targeting FcRn, today announced an expansion of its board
of directors with the appointment of Andrew Cheng, M.D., Ph.D., the
chief medical officer and an executive vice president at Gilead Sciences
(NYSE: GILD).

Dr. Cheng has a 20-year track record of accomplishments, including
leading the formulation of Phase 1-4 clinical development plans as well
as the filing and approval of NDA and MAA submissions for 11 approved
HIV products. His past roles at Gilead include leading the company’s
development operations, which covered clinical research support in
multiple therapeutic areas including oncology, inflammatory, respiratory
and cardiovascular indications as well as HIV and liver diseases. Dr.
Cheng holds an M.D. and a Ph.D. in cellular and molecular biology from
Columbia University.

I am delighted to welcome Dr. Cheng to the board,” said Seth Harrison,
M.D., chairman of the Syntimmune Board of Directors. “His experience in
building a world-class organization, with the ability to advance
products from clinical development through regulatory approval with
industry-leading speed, will be of great value to the company as we
continue to the next level of success.”

Jean-Paul Kress, M.D., Syntimmune’s president and CEO, said: “Under Dr.
Cheng’s leadership, Gilead has developed and received regulatory
approval for medicines that have transformed care for millions of people
around the world with HIV, viral hepatitis and other serious illnesses.
His clinical and scientific expertise will be tremendously beneficial as
we advance our programs focused on the treatment of patients with
IgG-mediated autoimmune diseases.”

About Syntimmune

Founded in 2013, Syntimmune is a clinical-stage biotechnology company
developing differentiated drug candidates in a wide range of autoimmune
diseases. Based on the pioneering and groundbreaking research of its
scientific founders, the company is advancing novel therapies based on
its deep expertise in the biology of the neonatal Fc receptor (FcRn) and
its complex role in the pathogenesis of IgG-mediated autoimmune
diseases. Syntimmune’s lead candidate, SYNT001, is a monoclonal antibody
that specifically blocks FcRn-IgG interactions and is being studied in
multiple Phase 1b/2a trials for the treatment of IgG-mediated autoimmune
diseases. Syntimmune is also developing SYNT002, which targets
FcRn-albumin interactions to facilitate the clearance of albumin-bound
toxins. Headquartered in Boston, Mass., Syntimmune has raised $78
million in private financing from leading life sciences investors led by
Apple Tree Partners. Investors also include Partners Innovation Fund,
FMB Research, and AFB Fund. For more information on Syntimmune, please
visit the company’s website at www.syntimmune.com.

Contacts

Syntimmune, Inc.
Adam Hansard, 617-890-9652
adam.hansard@syntimmune.com

Flex Pharma to Report First Quarter 2018 Financial Results on May 2, 2018

BOSTON–(BUSINESS WIRE)–$flksFlex
Pharma, Inc
. (NASDAQ: FLKS), a clinical-stage biotechnology company
that is developing innovative and proprietary treatments for cramps and
spasticity associated with severe neurological diseases such as multiple
sclerosis (MS), Charcot-Marie-Tooth (CMT) and amyotrophic lateral
sclerosis (ALS) under FDA Fast Track designation, announced today that
it will report its financial results for the first quarter ended March
31, 2018 on Wednesday, May 2, 2018 before the U.S. financial markets
open. The Company will host a conference call and webcast at 9:00 a.m.
ET to discuss first quarter 2018 financial results and provide a
business update. Individuals interested in participating in the call
should dial (855) 780-7202 (U.S. and Canada) or (631) 485-4874
(International).

A live webcast may be accessed in the Investors & Media section of the
Company’s website at www.flex-pharma.com.
Please log on to the Flex Pharma website approximately 15 minutes prior
to the scheduled webcast to ensure adequate time for any software
downloads that may be required. A replay of the webcast will be
available on Flex Pharma’s website for 90 days following the event.

About Flex Pharma

Flex Pharma, Inc. is a clinical-stage biotechnology company that is
developing innovative and proprietary treatments in Phase 2 randomized,
controlled trials for cramps and spasticity associated with the severe
neurological diseases of ALS, MS and peripheral neuropathies such as
Charcot-Marie-Tooth (CMT). The Company’s lead candidate, FLX-787, is
being developed under Fast Track designation for the treatment of severe
muscle cramps associated with ALS. Flex Pharma was founded by National
Academy of Science members Rod MacKinnon, M.D. (2003 Nobel Laureate),
and Bruce Bean, Ph.D., recognized leaders in the fields of ion channels
and neurobiology, along with Christoph Westphal, M.D., Ph.D.

Click
to Tweet this News

Contacts

Flex Pharma, Inc.
Elizabeth Woo, 617-874-1829
SVP, Investor
Relations & Corporate Communications
irdept@flex-pharma.com

#jobs #lifescience Warehouse Manager

Biotechnology, Pharma and Biopharma News – Research – Science – Lifescience ://Biotech-Biopharma-Pharma: Warehouse Manager .CA-Redwood City, We are currently hiring for a warehouse manager to work with a well established Biotech organization in Redwood City. This organization offers great perks such as; PTO, Catered Lunches, Fun Office environment, etc. This is a Monday through Friday position, overseeing 2-4 warehouse staff and ensuring the operations is ran smoothly. Your duties would include but are not limited to: – Communicate nee

from Monster Job Search Results biotech https://ift.tt/2JuaxPk

Five Prime to Present at 2018 ASCO Annual Meeting

SOUTH SAN FRANCISCO, Calif.–(BUSINESS WIRE)–Five
Prime Therapeutics, Inc.
(Nasdaq:FPRX), a clinical-stage
biotechnology company focused on discovering and developing innovative
immuno-oncology protein therapeutics, today announced that it will
present two posters during the 2018 American Society of Clinical
Oncology (ASCO) Annual Meeting, being held June 1-5, 2018, in Chicago.

Abstract Number and Title: #TPS4135, “FIGHT: A Phase 3
Randomized, Double-Blind, Placebo Controlled Study Evaluating
(Bemarituzumab) FPA144 and Modified FOLFOX6 (mFOLFOX6) in Patients with
Previously Untreated Advanced Gastric and Gastroesophageal Cancer with a
Dose Finding Phase 1 Lead-In”
Poster Session:
Gastrointestinal (Noncolorectal) Cancer
Session Date and Time:
Sunday, June 3, 2018; 8:00 – 11:30 a.m. CT
Location: Hall A,
Poster Board Number: #322a

Abstract Number and Title: #3020, “Pharmacodynamics (PD) and
Genomic Profiling of Pts Treated with cabiralizumab (cabira) + nivolumab
(NIVO) Provide Evidence of On-Target Tumor Immune Modulations and
Support Future Clinical Applications”
Poster Session:
Developmental Therapeutics – Immunotherapy
Session Date and Time:
Monday, June 4, 2018; 8:00 – 11:30 a.m. CT
Location: Hall A,
Poster Board Number: #234
Discussion Session Date and Time:
Monday, June 4, 2018; 11:30 a.m. – 12:45 p.m. CT
Discussion
Session Location:
Hall B1

About Bemarituzumab (FPA144)

Bemarituzumab
is an isoform-selective, humanized monoclonal antibody in clinical
development as a targeted immuno-therapy for tumors that overexpress
FGFR2b, a splice variant of a receptor for some members of the
fibroblast growth factor (FGF) family. Clinical results to date suggest
that the specificity of FPA144 avoids toxicities that have been seen
with less selective FGFR2 small molecule therapeutics. FPA144 has also
been engineered for enhanced antibody-dependent cell-mediated
cytotoxicity (ADCC) to increase direct tumor cell killing by recruiting
natural killer (NK) cells.

About Cabiralizumab (FPA008)

Cabiralizumab
is an investigational antibody that inhibits the CSF-1 receptor and has
been shown in preclinical models to block the activation and survival of
monocytes and macrophages. Inhibition of CSF1R in preclinical models of
several cancers reduces the number of immunosuppressive tumor-associated
macrophages (TAMs) in the tumor microenvironment, thereby facilitating
an immune response against tumors. Cabiralizumab is currently in
clinical trials in oncology indications and in pigmented villonodular
synovitis (PVNS). Cabiralizumab is being developed under an exclusive
worldwide license and collaboration agreement entered into with
Bristol-Myers Squibb (BMS) in October 2015.

About Five Prime

Five Prime Therapeutics, Inc. discovers and develops innovative
therapeutics to improve the lives of patients with serious diseases.
Five Prime’s comprehensive discovery platform, which encompasses
virtually every medically relevant extracellular protein, positions it
to explore pathways in cancer, inflammation and their intersection in
immuno-oncology, an area with significant therapeutic potential and the
focus of the company’s R&D activities. Five Prime has entered into
strategic collaborations with leading global pharmaceutical companies
and has promising product candidates in clinical and late preclinical
development. For more information, please visit www.fiveprime.com
or follow us on LinkedIn,
Twitter
and Facebook.

Cautionary Note on Forward-looking Statements

This press release contains forward-looking statements within the
meaning of the Private Securities Litigation Reform Act of 1995. Words
such as “may,” “will,” “expect,” “plan,” “anticipate,” “estimate,”
“intend” and similar expressions (as well as other words or expressions
referencing future events, conditions or circumstances) are intended to
identify forward-looking statements. These forward-looking statements
are based on Five Prime’s expectations and assumptions as of the date of
this press release. Each of these forward-looking statements involves
risks and uncertainties. Actual results may differ materially from these
forward-looking statements. Forward-looking statements contained in this
press release include statements about Five Prime’s potential receipt of
milestone payments and royalties. Many factors may cause differences
between current expectations and actual results, including unexpected
safety or efficacy data observed during non-clinical or clinical
studies, clinical site activation rates or clinical trial enrollment
rates that are lower than expected and changes in expected or existing
competition. Other factors that may cause actual results to differ from
those expressed or implied in the forward-looking statements in this
press release are discussed in Five Prime’s filings with the U.S.
Securities and Exchange Commission, including the “Risk Factors”
contained therein. Except as required by law, Five Prime assumes no
obligation to update any forward-looking statements contained herein to
reflect any change in expectations, even as new information becomes
available.

Contacts

Five Prime Therapeutics, Inc.
Heather Rowe, 415-365-5737
Senior
Director, Investor Relations and Corporate Communications
heather.rowe@fiveprime.com

Cell Dissociation Market by Product (Enzymatic, Non-enzymatic), Type (Tissue Dissociation), Tissue (Connective, Epithelial), End User (Pharmaceutical, Research Institutes) – Global Forecast to 2023 – ResearchAndMarkets.com

DUBLIN–(BUSINESS WIRE)–The “Cell
Dissociation Market by Product (Enzymatic (Collagenase, Trypsin, DNase,
Elastase) Non-enzymatic), Type (Tissue Dissociation), Tissue
(Connective, Epithelial), End User (Pharmaceutical, Research Institutes)
– Global Forecast to 2023”
report has been added to ResearchAndMarkets.com’s
offering.

The cell dissociation market is expected to reach USD 440.5 million by
2023 from USD 241.2 million in 2018, at a CAGR of 12.8%.

Factors driving the growth of this market include rising government
funding for chronic disease research and increasing R&D investment in
pharmaceutical & biotechnology companies. On the other hand, emerging
economies such as China, India, and Brazil are providing lucrative
opportunities for the players operating in the cell dissociation market.

Based on product, the market is segmented into enzymatic dissociation
products, non-enzymatic dissociation products, and instruments &
accessories market. Among all, the non-enzymatic product segment is
estimated to grow at the highest CAGR during the forecast period. This
can be primarily attributed to advantages such as ready to use and
non-toxic in nature.

On the basis of type, the market is segmented into tissue dissociation
and cell detachment. The tissue dissociation segment dominated the
market in 2017. Increasing demand for enzymatic products and instruments
& accessories in the pharmaceutical & biotechnology companies is the
major driving factor for this segment.

Geographically, the cell dissociation market was dominated by North
America, followed by Europe in 2017. However, Asia Pacific is estimated
to grow at the fastest rate due to infrastructural developments in the
life sciences industry, rising government investments for chronic
disease research, and presence of emerging economies such as China and
India.

Key Topics Covered:

1 Introduction

2 Research Methodology

3 Executive Summary

4 Premium Insights

5 Market Overview

6 Cell Dissociation Market, By Product

7 Cell Dissociation Market, By Tissue

8 Cell Dissociation Market, By Type

9 Cell Dissociation Market, By End User

10 Cell Dissociation Market, By Region

11 Competitive Landscape

12 Company Profiles

  • ATCC
  • BD
  • F. Hoffmann-La Roche Ltd.
  • GE Healthcare
  • Himedia Laboratories
  • Merck KGaA
  • Miltenyi Biotec
  • Pan-Biotech
  • Stemcell Technologies
  • Thermo Fisher Scientific

For more information about this report visit https://www.researchandmarkets.com/research/9tw655/cell_dissociation?w=4

Contacts

ResearchAndMarkets.com
Laura Wood, Senior Manager
press@researchandmarkets.com
For
E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call
1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
Related
Topics: Biotechnology